文献速递慢阻肺

慢性阻塞性肺疾病中的心血管疾病:叙述性综述

Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review.
PubMed 文献 · Thorax · 2022-06-30

本文为叙述性综述,探讨慢阻肺患者心血管疾病负担加重、生活质量下降、住院增加和生存期缩短的问题。急性加重与心血管事件增加相关,两者关联可能源于共同危险因素、共同病理生理通路、高患病率共现、慢阻肺及其急性加重对心血管的不良影响以及药物相互影响。综述涵盖发病率与患病率、慢阻肺亚型关联、共享病理生理与遗传、风险预测和治疗。

要点

  • 慢阻肺患者心血管疾病患病率高但可能被低估诊断。
  • 急性加重与心血管事件增加相关,是慢阻肺负担的重要来源。
  • 改善风险预测、诊断和治疗优化可能改善慢阻肺患者预后。

核心结论

  • 慢阻肺患者心血管疾病风险增加,合并心血管疾病导致生活质量下降、住院增加和生存期缩短。
  • 慢阻肺与心血管疾病的关联可能由共同危险因素、共同病理生理通路、高患病率共现、慢阻肺及急性加重对心血管的不良影响和药物相互影响所解释。
  • 改善风险预测、诊断和治疗优化可能改善慢阻肺患者的心血管结局。

研究设计与样本

  • 叙述性综述(state-of-the-art review),检索范围涵盖慢阻肺中心血管疾病的发病率与患病率、慢阻肺亚型关联、共享病理生理与遗传、风险预测和治疗。

主要发现

  • 慢阻肺患者心血管疾病患病率高,但可能被低估诊断。
  • 急性肺加重是慢阻肺负担的重要贡献因素,并与心血管事件增加相关。
  • 心血管风险传统上与慢阻肺疾病严重程度增加相关,但还存在其他慢阻肺亚型关联,包括影像学亚型、频繁急性加重者和新疾病聚类。
  • 慢阻肺和心血管疾病均造成显著全球疾病负担,理解两者关系可能减少该负担。
  • 心血管药物可能加重慢阻肺,反之亦然。

临床怎么用

  • 对慢阻肺患者应关注心血管疾病风险,注意急性加重与心血管事件的关联。
  • 重视慢阻肺患者心血管疾病可能被低估诊断的情况,改善风险预测和诊断。
  • 在慢阻肺治疗中考虑心血管药物与慢阻肺药物的相互影响,优化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular disease (CVD) and concomitant disease leads to reduced quality of life, increased hospitalisations and worse survival. Acute pulmonary exacerbations are an important contributor to COPD burden and are associated with increased cardiovascular (CV) events. Both COPD and CVD represent a significant global disease impact and understanding the relationship between the two could potentially reduce this burden. The association between CVD and COPD could be a consequence of (1) shared risk factors (environmental and/or genetic) (2) shared pathophysiological pathways (3) coassociation from a high prevalence of both diseases (4) adverse effects (including pulmonary exacerbations) of COPD contributing to CVD and (5) CVD medications potentially worsening COPD and vice versa. CV risk in COPD has traditionally been associated with increasing disease severity, but there are other relevant COPD subtype associations including radiological subtypes, those with frequent pulmonary exacerbations and novel disease clusters. While the prevalence of CVD is high in COPD populations, it may be underdiagnosed, and improved risk prediction, diagnosis and treatment optimisation could lead to improved outcomes. This state-of-the-art review will explore the incidence/prevalence, COPD subtype associations, shared pathophysiology and genetics, risk prediction, and treatment of CVD in COPD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Balbirsingh V, Mohammed AS, Turner AM, et al. Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. Thorax. 2022. PMID: 35772939. doi:10.1136/thoraxjnl-2021-218333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。